Overview

Trial of Abiraterone Without Exogenous Glucocorticoids in Men With CRPC With Correlative Assessment of Hormone Intermediates.

Status:
Active, not recruiting

Trial end date:
2022-06-01

Target enrollment:

Participant gender:

Summary

This study is comparing the safety and effectiveness of abiraterone acetate alone, followed by the addition of prednisone (when the participant's disease worsens or the physician feels it would lessen symptoms of toxicity) versus the current approved treatment regimen which involves the concomitant use of prednisone in conjunction with abiraterone acetate. Additionally, this study is also examining why participants stop responding to treatment with abiraterone acetate by evaluating blood and tissue.

Phase:

Phase 2

Details

Lead Sponsor:

Dana-Farber Cancer Institute

Collaborator:

Janssen Research & Development, LLC

Treatments:

Abiraterone Acetate
Glucocorticoids
Hormones
Mineralocorticoids
Prednisone